Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claim that OZEMPIC carries a risk concern for thyroid C-cell tumors (including MTC) is directly supported by the FDA label’s Warnings/Precautions and contraindications, including the statement that rodent findings’ human relevance is unknown.
Category Scores
Accurate Statements
Risk of thyroid C-cell tumors (including MTC) with OZEMPIC.
Supported by Prescribing Information section 5.1 (Risk of Thyroid C-Cell Tumors), which describes semaglutide-induced thyroid C-cell tumors in mice/rats and states it is unknown whether OZEMPIC causes such tumors in humans, and includes counseling re MTC symptoms.
The label states human relevance is unknown for thyroid C-cell tumors, and patient counseling is provided for thyroid tumor symptoms.
Supported by section 5.1 and section 17 (Patient Counseling Information).
Contraindications exist for patients with a personal or family history of MTC or MEN 2.
Supported by section 4 (Contraindications) and referenced in section 5.1.
Unsupported Statements
Contradictions
Important Omissions
The response does not explicitly mention the note that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection (and may increase unnecessary procedures), which is part of the same Warnings/Precautions topic.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated content accurately reflects a labeled safety concern and related contraindications/counseling; no additional dosing or misuse guidance is provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Suggested Improvement
Optionally include that routine monitoring with serum calcitonin or thyroid ultrasound is of uncertain value and may lead to unnecessary procedures, as stated in section 5.1.